Krilogy Financial LLC Has $937,000 Position in Exelixis, Inc. $EXEL

Krilogy Financial LLC reduced its stake in shares of Exelixis, Inc. (NASDAQ:EXEL) by 31.7% during the 1st quarter, HoldingsChannel reports. The fund owned 21,111 shares of the biotechnology company’s stock after selling 9,791 shares during the period. Krilogy Financial LLC’s holdings in Exelixis were worth $937,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Brookstone Capital Management increased its position in Exelixis by 31.6% in the 1st quarter. Brookstone Capital Management now owns 21,158 shares of the biotechnology company’s stock worth $907,000 after purchasing an additional 5,076 shares during the last quarter. SG Americas Securities LLC grew its stake in shares of Exelixis by 39.2% in the 1st quarter. SG Americas Securities LLC now owns 50,495 shares of the biotechnology company’s stock valued at $2,166,000 after buying an additional 14,207 shares in the last quarter. BI Asset Management Fondsmaeglerselskab A S increased its holdings in Exelixis by 248.9% in the first quarter. BI Asset Management Fondsmaeglerselskab A S now owns 152,320 shares of the biotechnology company’s stock worth $6,533,000 after buying an additional 108,662 shares during the last quarter. Gunpowder Capital Management LLC dba Oliver Wealth Management bought a new position in Exelixis during the fourth quarter valued at approximately $192,000. Finally, Wick Capital Partners LLC acquired a new stake in Exelixis in the fourth quarter valued at approximately $235,000. 85.27% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other news, CFO Christopher J. Senner sold 34,901 shares of the business’s stock in a transaction dated Monday, May 18th. The shares were sold at an average price of $50.00, for a total transaction of $1,745,050.00. Following the transaction, the chief financial officer owned 952,317 shares in the company, valued at approximately $47,615,850. The trade was a 3.54% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director George Poste sold 60,000 shares of the company’s stock in a transaction dated Thursday, May 7th. The shares were sold at an average price of $45.71, for a total transaction of $2,742,600.00. Following the transaction, the director directly owned 118,832 shares of the company’s stock, valued at $5,431,810.72. This represents a 33.55% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 219,170 shares of company stock worth $10,620,641. Corporate insiders own 2.60% of the company’s stock.

Exelixis Stock Up 2.9%

Shares of NASDAQ:EXEL opened at $54.77 on Friday. The company has a market cap of $13.77 billion, a price-to-earnings ratio of 18.20, a PEG ratio of 1.53 and a beta of 0.41. The business has a 50 day moving average price of $49.59 and a 200 day moving average price of $45.50. Exelixis, Inc. has a twelve month low of $33.76 and a twelve month high of $55.15.

Exelixis (NASDAQ:EXEL) last issued its quarterly earnings results on Tuesday, May 5th. The biotechnology company reported $0.87 EPS for the quarter, topping the consensus estimate of $0.75 by $0.12. Exelixis had a return on equity of 39.89% and a net margin of 35.08%.The company had revenue of $610.81 million for the quarter, compared to the consensus estimate of $607.51 million. During the same period in the previous year, the business posted $0.55 EPS. The company’s revenue for the quarter was up 10.0% on a year-over-year basis. Analysts anticipate that Exelixis, Inc. will post 3.16 EPS for the current year.

Analysts Set New Price Targets

Several brokerages have recently commented on EXEL. TD Cowen increased their price target on shares of Exelixis from $51.00 to $55.00 and gave the stock a “buy” rating in a research note on Wednesday, May 6th. Barclays boosted their price target on Exelixis from $44.00 to $45.00 and gave the stock an “equal weight” rating in a research report on Monday, April 20th. HC Wainwright boosted their target price on Exelixis from $54.00 to $56.00 and gave the stock a “buy” rating in a report on Thursday, May 7th. Wall Street Zen raised shares of Exelixis from a “buy” rating to a “strong-buy” rating in a research report on Saturday, May 9th. Finally, Wells Fargo & Company upped their price objective on shares of Exelixis from $35.00 to $40.00 and gave the stock an “equal weight” rating in a report on Wednesday, May 6th. Eight equities research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, Exelixis has an average rating of “Hold” and a consensus target price of $46.87.

Exelixis Profile

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.